Momenta Pharmaceuticals, Inc.
https://www.momentapharma.com/home/default.aspx
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Momenta Pharmaceuticals, Inc.
J&J's Next Immunology Act Centers On Nipocalimab For Autoantibody-Driven Diseases
The company has ramped up a broad R&D program for the FcRn inhibitor in 11 autoantibody-driven disease areas.
Tech Transfer Roundup: Athenex, PDS Align With National Cancer Institute On Oncology R&D
Athenex expands its portfolio of T-cell receptor therapy technology under NCI license agreement; PDS Biotechnology accesses institute’s TARP tumor antigen technology.
Finance Watch: CF Foundation Commits $110m In Partnership With Flagship’s Pioneering Medicines
Private Company Edition: Flagship’s Pioneering Medicines initiative and the firm’s portfolio companies will deliver cystic fibrosis drug candidates. Also, recent venture capital financings include cloud technology firm Saama’s $430m round and Shoreline’s $140m in new funding.
Are Regeneron And Pfizer/BioNTech COVID-19 Products Covered By Patent Safe Harbor?
Allele claims Regeneron’s monoclonal antibody cocktail and Pfizer/BioNTech’s COVID-19 vaccine infringe its fluorescent protein patent. Regeneron asks court to toss suit against it, arguing use of protein for FDA submission is protected. A different court denied Pfizer/BioNTech’s motion to dismiss similar suit.
Company Information
- Industry
- Pharmaceuticals
-
Biotechnology
- Drug Discovery Tools
-
Large Molecule
- Antibodies
- Other Names / Subsidiaries
-
- Mimeon, Inc.